Lenmid
Lenmid (Lenalidomide 5/10/25 mg) — second-generation IMiD for multiple myeloma, MDS-5q, and mantle cell lymphoma. Mandatory pregnancy prevention programme.
✓ Medicinsk gennemgået af Morgan Ellis — Apoteksforsker · 8 års erfaring · Sidst gennemgået: maj 2026
Hurtigt svar
Lenmid — Lenalidomide 5/10/25 mg (WHO-GMP certified manufacturer). Immunomodulatory drug (IMiD) for multiple myeloma (newly diagnosed and relapsed/refractory), 5q-myelodysplastic syndrome, and mantle cell lymphoma. Modern IMiD with greater potency and fewer neuropathy/sedation side effects than thalidomide.
Hvad du får med MedsBase:
- WHO-GMP certificeret producent
- Diskret kuvertemballage uden mærkning
- Levering til hele verden
- Bedømt af 1.400+ kunder (læs anmeldelser)
📦 Genforsendelsesgaranti: hvis din ordre ikke er ankommet inden for 20 hverdage efter afsendelse, genforsender vi den uden ekstra omkostninger. Læs politikken.
Hvorfor bestille fra MedsBase
Lenmid ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialistsuperviseret kræftbehandling — denne medicin påbegyndes, overvåges og afsluttes af en onkolog eller hæmatolog. Dosering afhænger af tumortype, stadium, kropsoverflade, organfunktion og samtidig behandling. Selvbehandling er ikke relevant; oplysningerne nedenfor er uddannelsesmæssige og støtter informerede samtaler med din specialist.
All IMiDs are severely teratogenic (thalidomide most notoriously — phocomelia). Mandatory pregnancy-prevention programme (REMS/iCare equivalent): pregnancy testing before, during, and after; two effective contraceptive methods; counselling for both partners; no blood donation during therapy or for 4 weeks after. Even one dose during pregnancy can cause severe malformations.
IMiDs carry significantly elevated risk of deep vein thrombosis and pulmonary embolism, especially in combination with corticosteroids or doxorubicin. Mandatory thromboprophylaxis: low-dose aspirin (low-risk), or LMWH/warfarin/DOAC (higher-risk patients). Specialist-determined.
All IMiDs cause myelosuppression — neutropenia, thrombocytopenia, anaemia. Weekly FBC during initiation; monthly maintenance. Renal dose adjustment (lenalidomide especially — significant renal accumulation).
Ofte stillede spørgsmål
Hvornår anvendes dette?
Immunomodulatory drug (IMiD) for multiple myeloma (newly diagnosed and relapsed/refractory), 5q-myelodysplastic syndrome, and mantle cell lymphoma. Modern IMiD with greater potency and fewer neuropathy/sedation side effects than thalidomide.
Hvordan indtages det?
Once daily, typically in cycles (e.g., 21 days on, 7 days off for lenalidomide). Specific dose and schedule are myeloma-protocol-specific (Rd, RVd, KRd, etc.). Specialist-determined by tumour response and tolerability.
Pregnancy prevention?
Mandatory programme: monthly pregnancy tests, two effective contraceptive methods, partner contraception, counselling. Even one dose during pregnancy causes severe malformations. No blood donation during therapy or for 4 weeks after stopping.
Almindelige bivirkninger?
IMiD class: VTE, fatigue, rash, GI (constipation, diarrhoea), myelosuppression. Lenalidomide: less neuropathy than thalidomide. Pomalidomide: often better tolerated than thalidomide; renal-friendly. Thalidomide: peripheral neuropathy, sedation.
Lægemiddelinteraktioner?
Anticoagulants — adjust based on VTE prophylaxis strategy. Digoxin levels may rise. Erythropoietin agents + IMiD — increased thrombosis risk; use only with mandatory thromboprophylaxis.
Nyreovervågning?
Lenalidomide: dose-adjust by CrCl (significant renal accumulation). Pomalidomide: less renal effect but still monitor. Thalidomide: renally cleared metabolite — monitor renal function.
Hvad hvis jeg glemmer en dosis?
Take when you remember if <12 hours late; otherwise skip and resume — do not double up. Notify oncology team if multiple doses missed.
Vaccination?
Inactivated vaccines OK; live vaccines contraindicated during IMiD therapy. Optimise vaccinations before starting if possible.
Langtidskomplikationer?
IMiD therapy: secondary primary malignancies (especially with extended use), cumulative VTE risk, neuropathy (thalidomide especially).
When is treatment stopped?
Specialist-determined: response duration, toxicity, planned treatment break, transition to maintenance therapy. IMiD maintenance therapy is now standard in myeloma — typically lenalidomide post-autologous stem cell transplant continued for 2-3 years or until intolerance.
Andre kræftlægemidler
- Xeloda — capecitabin 500 mg — oral 5-FU prodrug til bryst-/tyktarms-/mavekræft
- Altraz — anastrozole 1 mg — aromathæmmermiddel til postmenopausalt brystkræft
- Xbira — abiraterone 250 mg — CYP17-hæmmer til metastatisk prostatakræft
- Zoldria — zoledronsyre IV — til knoglemetastaser og hyperkalcæmi
- Actorise — darbepoetin alfa — til kemoterapi-induceret anæmi
Flere muligheder inden for kræftmedicin
Rangeret efter seneste MedsBase ordrevolumen — hvad andre kunder i denne kategori vælger.
| Styrke | 5 mg, 10 mg, 25 mg |
|---|---|
| Antal | 30 kapsler, 60 kapsler, 90 kapsler |
| Farmaceutisk form | Kapsel(er) |
| Producent | Cipla Inc |
| Behandling | Multiple myeloma, Lepra reaction |
| Generisk mærke | Lenalidomide |
Lenmid
Spørgsmål & svar
Lenmid
Relaterede produkter
Anmeldelser
Der er ingen anmeldelser endnu